Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bausch & Lomb Goes Private Under $4.5 Bil. Warburg Pincus Buyout

This article was originally published in The Gray Sheet

Executive Summary

Ophthalmic device firm Bausch & Lomb's acceptance of a $4.5 billion private equity buyout offer from Warburg Pincus leaves the door open for a higher bid by early July, according to B&L

You may also be interested in...



News In Brief

Obama signs appropriations bill giving FDA expanded user fee access. Bausch & Lomb IPO. More news.

Lifecore Set To Go Private Under $239 Million Warburg Pincus Buyout Deal

Dental implant maker Lifecore Biomedical is on-track to be acquired by private equity firm Warburg Pincus for $239 million after failing to receive a superior proposal, the firm said Feb. 14

Lifecore Set To Go Private Under $239 Million Warburg Pincus Buyout Deal

Dental implant maker Lifecore Biomedical is on-track to be acquired by private equity firm Warburg Pincus for $239 million after failing to receive a superior proposal, the firm said Feb. 14

Related Content

UsernamePublicRestriction

Register

MT024807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel